
◆ Mayank Goyal

Department of Radiology, University of Calgary

PS 2 - 2

Mayank Goyal is a Professor in the Department of Radiology and Clinical Neurosciences at the University of Calgary. He is the Director of Imaging and Endovascular treatment at the Calgary Stroke Program. He is also the Medical Director of the Seaman Family MR Research Centre. Dr. Goyal's passion and main research interest is acute stroke imaging, workflow and intervention. He has over 180 publications in peer-reviewed journals. He is one of the Principal Investigators in two global multi-centric trials in the field: ESCAPE and SWIFT PRIME (both published recently in NEJM). He was also the core-lab for the REVASCAT trial (published recently in NEJM). He is also the Co-PI of a CIHR funded study called PROVE IT. Dr. Goyal is world renowned for his ground-breaking work in efficiency and workflow in acute stroke intervention. He has extensively traveled across the world as a consequence of this expertise and has been one of the key components that helped the Calgary Stroke Program in becoming one of the best acute stroke programs in the world. In addition, Mayank is an innovator and is always thinking of solutions to problems. He also came up with a new way of imaging in acute stroke called multiphase CT angiography. This technique subsequently became the basis for the PROVE IT study (which is study doing a head to head comparison between multiphase CTA and CT perfusion) and was implemented globally as part of the ESCAPE study. Initial results and feedback suggest that the technique is extremely useful and saves on average 20 minutes in acute stroke treatment (published in Radiology). With the success of ESCAPE and SWIFT PRIME, Dr. Goyal has been an integral part of changing stroke care across the world and helping thousands of patients have a good outcome from what is otherwise a devastating disease. He is leading a meta-analysis (called HERMES) consisting of the recent 7 positive trials published in NEJM. The first paper from HERMES was recently published in Lancet (Mayank as first author). Dr. Goyal and the Calgary Stroke Program are starting the ESCAPE2 trial testing the usefulness of neuroprotection along with endovascular thrombectomy.

